Xylem Inc. XYL
Xylem overpaid in stock for SEC-fraud-charged Evoqua, just published two contradictory cash-flow statements, and faces 30-45% downside as multiples compress toward water-industrial peers.
Thesis
Spruce Point argues that Xylem, an S&P 500 water-infrastructure company, destroyed value by paying a 22x EBITDA all-stock premium for Evoqua Water Technologies, a private-equity roll-up the SEC has charged with revenue-recognition fraud and the U.S. Attorney's office is still investigating. After a forensic review, Spruce Point identifies two divergent sets of H1-2023 cash-flow statements (off by $86m on operating cash) and finds that Xylem buried $90m of cost-to-achieve inside its $140m headline synergy claim, while former executives call the deal 'crazy expensive' and warn revenue synergies should be marked at zero. Governance concerns compound the case: CEO Patrick Decker entered a 10b5-1 sale program two weeks after announcing the deal, and Audit Chair Victoria Harker previously served as CFO of WorldCom's MCI Group. Spruce Point models 30-45% downside to $58-$74/share versus a $105 print.
SCQA
Xylem is an S&P 500 water-technology company that just closed a $7.5 billion all-stock acquisition of Evoqua Water Technologies, promising $140m of cost synergies and an accretive, value-creating combination.
Evoqua was charged by the SEC with revenue-recognition fraud and remains under DOJ investigation; Xylem has published two divergent sets of cash-flow statements and former executives describe the 22x EBITDA price as 'crazy expensive' and dilutive.
Investors should reject management's narrative, demand CEO Patrick Decker resign, vote against Audit Chair Victoria Harker, and pressure regulators to widen the federal probe into Evoqua before more shoes drop.
Spruce Point estimates 30-45% downside to a $58-$74 share price (versus $105) as Xylem's premium multiple compresses toward water and industrial peers carrying higher margins and less leverage.
The three reasons
- 1
Xylem published two contradictory sets of H1-2023 cash-flow statements off by $86m
- 2
Paid 22x EBITDA for SEC-fraud-charged Evoqua after promising accretive deals only
- 3
Audit Chair Harker was CFO at WorldCom's MCI Group during the historic accounting fraud
Primary demands
- CEO Patrick Decker should resign
- Vote against Audit Chair Victoria Harker at the next director election
- Regulators should expand the scope of the federal investigation into Evoqua
- Xylem must transparently quantify the $90m of cost-to-achieve synergies
- Xylem must quantify revenue dis-synergies and intercompany overlap with Evoqua
KPIs cited
Pattern membership
Precedents cited
- Spruce Point Generac (GNRC) short, June 2022 (-60%)
- Spruce Point Mettler-Toledo (MTD) short, July 2019 (-22%)
- Spruce Point A.O. Smith (AOS) short, May 2019 (-30%)
- Victoria Harker tenure at WorldCom / MCI Group accounting fraud
- Xylem's prior failed acquisitions of Sensus and Pure Technologies
- Generac COO Thomas Pettit's resignation prior to joining Xylem
Composition what's on the 82 slides
Slide gallery ·
Notes
Cinematic AI-generated cover image (rusty leaking pipe with a rat) is a Spruce-Point signature and reinforces the 'leak in the bull case' frame. Standout rhetorical move is side-by-side display of two SEC-vs-website cash-flow statements (p10) — concrete, visual, and damning. 'Perception vs. Spruce Point Reality' table on p9 is a clean before/after device. Generac analogue (p12) doubles as a track-record flex and a prediction. WorldCom/MCI Group precedent attached to the Audit Chair adds personal-stakes governance angle. No stake size disclosed (typical for short reports). Author of record is the firm; Spruce Point is led by Ben Axler but the deck is not personally signed.